Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2017

27.07.2017 | Original Article – Cancer Research

Opa interacting protein 5 acts as an oncogene in bladder cancer

verfasst von: Xuefeng He, Jianquan Hou, Jigen Ping, Duangai Wen, Jun He

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the biological functions and mechanism of Opa interacting protein 5 (OIP5) in bladder cancer (BC).

Methods

We investigated the expression of OIP5 in BC through immunohistochemical staining (IHC) and its correlation with clinicopathologic features of BC patients. Moreover, knockdown of OIP5 was performed in BC cell lines and colony formation capacity, cell growth curve, cell cycle phase and cell apoptosis assay was applied for investigating the roles of OIP5 in BC. Moreover, the expression of OIP5 was validated through the Cancer Genome Atlas (TCGA) database. The diagnosis value of OIP5 was accessed by receiver operating characteristic (ROC) analysis in TCGA database.

Results

The expression of OIP5 in BC tissues was significantly higher than that in adjacent non-tumor tissues and bladder mucosa tissues with chronic cystitis. Higher protein expression level of OIP5 predicted shorter survival time in patients with BC, which was significantly correlated with larger tumor size, high-grade tumor and advanced T classification. The expression of OIP5 was considerably decreased after lentivirus infection both at mRNA and protein levels. Functional assay displayed that silencing of OIP5 inhibited colony formation capacity and cell growth in BC cell lines. Cell cycle assays indicated that suppressed OIP5 disturbed the balance of the cell cycle in BC cell lines, which increased the cell population of the G1 phase and decreased the cell population of the S phase. Furthermore, knockdown of OIP5 expression enhanced cell apoptosis process. The expression of OIP5 was significantly up-regulated in BC compared with adjacent non-tumor tissues based on TCGA database. OIP5 had the potential diagnostic value for BC.

Conclusions

Our work demonstrated that OIP5 might function as an oncogene to promote colony formation capacity and cell growth, arrest cell cycle and suppress cell apoptosis in bladder cancer.
Literatur
Zurück zum Zitat Chun HK, Chung KS, Kim HC, Kang JE, Kang MA, Kim JT, Choi EH, Jung KE, Kim MH, Song EY, Kim SY, Won M, Lee HG (2010) OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep 43(5):349–354CrossRefPubMed Chun HK, Chung KS, Kim HC, Kang JE, Kang MA, Kim JT, Choi EH, Jung KE, Kim MH, Song EY, Kim SY, Won M, Lee HG (2010) OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep 43(5):349–354CrossRefPubMed
Zurück zum Zitat Fu J, Luo B, Guo WW, Zhang QM, Shi L, Hu QP, Chen F, Xiao SW, Xie XX (2015) Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. Int J Clin Exp Pathol 8(7):7786–7797PubMedPubMedCentral Fu J, Luo B, Guo WW, Zhang QM, Shi L, Hu QP, Chen F, Xiao SW, Xie XX (2015) Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. Int J Clin Exp Pathol 8(7):7786–7797PubMedPubMedCentral
Zurück zum Zitat Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L (2006) Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108(13):4109–4117. doi:10.1182/blood-2006-01-023127 CrossRefPubMed Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L (2006) Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108(13):4109–4117. doi:10.​1182/​blood-2006-01-023127 CrossRefPubMed
Zurück zum Zitat Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2):199–208CrossRefPubMed Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2):199–208CrossRefPubMed
Zurück zum Zitat Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T (2007) Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26(44):6448–6455. doi:10.1038/sj.onc.1210466 CrossRefPubMed Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T (2007) Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26(44):6448–6455. doi:10.​1038/​sj.​onc.​1210466 CrossRefPubMed
Zurück zum Zitat Lerut E, Van Poppel H, Joniau S, Gruselle O, Coche T, Therasse P (2015) Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. Int J Clin Exp Pathol 8(8):9522–9532PubMedPubMedCentral Lerut E, Van Poppel H, Joniau S, Gruselle O, Coche T, Therasse P (2015) Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. Int J Clin Exp Pathol 8(8):9522–9532PubMedPubMedCentral
Zurück zum Zitat Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J, Zheng S, Pang X, Zhou S, Dang Y, Li L (2016) FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. Oncotarget. doi:10.18632/oncotarget.13790 Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J, Zheng S, Pang X, Zhou S, Dang Y, Li L (2016) FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. Oncotarget. doi:10.​18632/​oncotarget.​13790
Zurück zum Zitat Mengus C, Schultz-Thater E, Coulot J, Kastelan Z, Goluza E, Coric M, Spagnoli GC, Hudolin T (2013) MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. Int J Cancer J Int du Cancer 132(10):2459–2463. doi:10.1002/ijc.27914 CrossRef Mengus C, Schultz-Thater E, Coulot J, Kastelan Z, Goluza E, Coric M, Spagnoli GC, Hudolin T (2013) MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas. Int J Cancer J Int du Cancer 132(10):2459–2463. doi:10.​1002/​ijc.​27914 CrossRef
Zurück zum Zitat Naetar N, Hutter S, Dorner D, Dechat T, Korbei B, Gotzmann J, Beug H, Foisner R (2007) LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit. J Cell Sci 120(Pt 5):737–747. doi:10.1242/jcs.03390 CrossRefPubMed Naetar N, Hutter S, Dorner D, Dechat T, Korbei B, Gotzmann J, Beug H, Foisner R (2007) LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit. J Cell Sci 120(Pt 5):737–747. doi:10.​1242/​jcs.​03390 CrossRefPubMed
Zurück zum Zitat Qin J, Li D, Zhou Y, Xie S, Du X, Hao Z, Liu R, Liu X, Liu M, Zhou J (2016) Apoptosis-linked gene 2 promotes breast cancer growth and metastasis by regulating the cytoskeleton. Oncotarget. doi:10.18632/oncotarget.13740 Qin J, Li D, Zhou Y, Xie S, Du X, Hao Z, Liu R, Liu X, Liu M, Zhou J (2016) Apoptosis-linked gene 2 promotes breast cancer growth and metastasis by regulating the cytoskeleton. Oncotarget. doi:10.​18632/​oncotarget.​13740
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29CrossRefPubMed Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29CrossRefPubMed
Zurück zum Zitat Williams JM, Chen GC, Zhu L, Rest RF (1998) Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol Microbiol 27(1):171–186CrossRefPubMed Williams JM, Chen GC, Zhu L, Rest RF (1998) Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol Microbiol 27(1):171–186CrossRefPubMed
Zurück zum Zitat Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH (2013) Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol 30(1):368. doi:10.1007/s12032-012-0368-8 CrossRefPubMed Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH (2013) Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol 30(1):368. doi:10.​1007/​s12032-012-0368-8 CrossRefPubMed
Zurück zum Zitat Zhang J, Yang Z, Ou J, Xia X, Zhi F, Cui J (2016) The F-box protein FBXL18 promotes glioma progression by promoting K63-linked ubiquitination of Akt. FEBS Lett. doi:10.1002/1873-3468.12521 Zhang J, Yang Z, Ou J, Xia X, Zhi F, Cui J (2016) The F-box protein FBXL18 promotes glioma progression by promoting K63-linked ubiquitination of Akt. FEBS Lett. doi:10.​1002/​1873-3468.​12521
Metadaten
Titel
Opa interacting protein 5 acts as an oncogene in bladder cancer
verfasst von
Xuefeng He
Jianquan Hou
Jigen Ping
Duangai Wen
Jun He
Publikationsdatum
27.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2485-4

Weitere Artikel der Ausgabe 11/2017

Journal of Cancer Research and Clinical Oncology 11/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.